Zobrazeno 1 - 10
of 73
pro vyhledávání: '"Karl Patterson"'
Autor:
Ben Haycroft, Abigail Stevenson, Richard Stork, Stuart Gaffney, Philip Morgan, Karl Patterson, Ana Jovanovic
Publikováno v:
Orphanet Journal of Rare Diseases, Vol 18, Iss 1, Pp 1-14 (2023)
Abstract Background Fabry disease is a rare, progressive X-linked lysosomal storage disorder. It is caused by mutations in the GLA gene resulting in deficiency of α-galactosidase A (α-Gal A), leading to peripheral neuropathy, cardiovascular disease
Externí odkaz:
https://doaj.org/article/573d203946b24b62b1a3f2c4c1a8911e
Publikováno v:
Value in Health. 23:191-199
Background Changes in the regulatory context enable faster approval of transformative medicines. They also lead to health technology assessment (HTA) agencies having to make decisions with less evidence. In response, HTA agencies have also initiated
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1ccd8c1266e56641182b064e8abfcfa9
https://doi.org/10.1016/j.jval.2019.09.001
https://doi.org/10.1016/j.jval.2019.09.001
Autor:
Schmidt, Karl Patterson
Publikováno v:
Evolution, 1950 Mar 01. 4(1), 79-86.
Externí odkaz:
https://www.jstor.org/stable/2405535
Autor:
Schmidt, Karl Patterson
Publikováno v:
The Auk, 1950 Apr 01. 67(2), 183-189.
Externí odkaz:
https://www.jstor.org/stable/4081211
Autor:
Schmidt, Karl Patterson
Publikováno v:
The Quarterly Review of Biology, 1954 Dec 01. 29(4), 322-331.
Externí odkaz:
https://www.jstor.org/stable/2815363
Autor:
Schmidt, Karl Patterson
Publikováno v:
Copeia, 1932 Apr 01. 1932(1), 6-9.
Externí odkaz:
https://www.jstor.org/stable/1437020
Autor:
Schmidt, Karl Patterson
Publikováno v:
Copeia, 1946 Oct . 1946(3), 144-152.
Externí odkaz:
https://www.jstor.org/stable/1438736
Autor:
Karl Patterson, Oliver Hale, Blanca Homet Moreno, Yang Meng, Yizhen Lai, Haojie Li, Ronac Mamtani, James Luke Godwin
Publikováno v:
Clinical genitourinary cancer. 19(1)
Introduction Pembrolizumab has been approved in the United States (US) for the first-line treatment of patients with advanced or metastatic urothelial carcinoma, who are ineligible for cisplatin-containing chemotherapy and with tumors expressing prog
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9283c21d50efa1fd469647775a0df306
https://pubmed.ncbi.nlm.nih.gov/32826180
https://pubmed.ncbi.nlm.nih.gov/32826180
Autor:
Haojie Li, Rachael Batteson, James M. Pellissier, Yang Meng, Ronald de Wit, Petros Grivas, Vimalanand S. Prabhu, Ruifeng Xu, Yichen Zhong, Stephen Michael Keefe, Karl Patterson, Natalie Zarabi
Publikováno v:
European urology oncology, 2(5), 565-571. Elsevier
Background There is an unmet need for effective therapies for patients with advanced or metastatic urothelial cancer who cannot tolerate cisplatin-based chemotherapy. Cisplatin-ineligible patients experience a high frequency of adverse events from th
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::728c0411b23d915b616510e9babf01b0
https://pure.eur.nl/en/publications/71067981-0614-45c5-9106-8c49b6b3e704
https://pure.eur.nl/en/publications/71067981-0614-45c5-9106-8c49b6b3e704
Autor:
Schmidt, Karl Patterson
Publikováno v:
The Scientific Monthly, 1946 Mar 01. 62(3), 230-232.
Externí odkaz:
https://www.jstor.org/stable/18986